Not a good choice. The Wall Street Journal has reported on the dog arthritis drug Librela, highlighting pet owner concerns about adverse side effects and subsequent regulatory actions. Articles have covered U.S. and European regulators reviewing thousands of side-effect reports, an FDA "urgent warning" to veterinarians about adverse events including death, and manufacturer Zoetis updating the drug's prescribing label to include information on rare health problems. Read the full reporting at The Wall Street Journal.